Spine

SpineGuard[®] receives FDA clearance to market its DSG[™] integration module for making pedicle screws "smart"

Initial US commercialization to begin immediately, will be in combination with Zavation's pedicle screw system



PARIS and SAN FRANCISCO, January 16, 2017 – SpineGuard (FR0011464452 – ALSGD), an innovative company that develops and markets disposable medical devices to make spine surgery safer, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new **DSG™** (**Dynamic Surgical Guidance**) integration module to be used in combination with Zavation's spinal fusion system to make its pedicle screws "smart."

"This FDA clearance will allow US spine surgeons to insert pedicle screws 'with a DSG enabled device' not only in just one step but also with confidence, hence further securing and streamlining the most commonly performed instrumented spinal procedure, fusion. We are thrilled to immediately begin supplying Zavation, our US partner, with our DSG[™] integration module and look forward to working with our combined networks for the introduction of the first DSG-enabled pedicle screw in the US market," said Pierre Jérôme, CEO and Co-founder of SpineGuard.

A DSG[™]-enabled screw is the unique combination of a bipolar sensor and a pedicle screw in just one device. The technology offers surgeons real-time guidance and the ability to insert the screw directly into a vertebra without drilling a pilot hole. In minimally invasive surgery, it also obviates the need for a k-wire.

The DSG[™] sensor differentiates various tissue types (cancellous bone, cortical bone, blood and soft tissues) based on the analysis of the local electrical conductivity. Real-time feedback informs the surgeon of changes in tissue type by an audio signal varying in pitch and cadence. This in turn alerts the surgeon of potential breaches during pedicle screw placement and allows for screw redirection.

The outcome is a single-step pedicle screw insertion with a high degree of accuracy, reduced radiation exposure and streamlined surgical steps resulting in potential time and cost savings.

During the recent annual meeting of the North American Spine Society (NASS) in Boston, SpineGuard received an award from *Orthopedics this Week* recognizing the DSG[™] Screw as one of the BEST new spine care technologies.

Another DSG[™]-enabled SmartScrew co-developed with Neuro France Implants (*La ville-aux-Clercs, France*) is currently in alpha launch in Europe with seven surgeons having started to use the system.

"DSG[™] enabled devices offer a new paradigm to pedicle screw manufacturers who wish to differentiate their products from the rank-and-file screws in the market today. We are extremely pleased that our first DSG-partner in the USA is Zavation, and we look forward to extending this technology platform to other players in the industry", concluded Stéphane Bette, Co-founder, CTO and US General Manager of SpineGuard.

More information on the DSG[™] technology, its new applications and surgeons' testimonials here.

Latest news release: 2016 full year revenue, January 5, 2017

Next financial press release: 2016 full year financial results, March 23, 2017 SpineGuard will attend the 'Invest Securities Biomed Event' in Paris, on January 26, 2017.

About SpineGuard®

Co-founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard's mission is to make spine surgery safer by bringing real-time digital technology into the operating room. Its primary objective is to establish its proprietary DSG[™] (Dynamic Surgical Guidance) technology as the global standard of surgical care, starting with safer screw placement in spine surgery and then in other surgeries. PediGuard[®], the first device designed using DSG, was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. It is the world's first and only handheld device capable of alerting surgeons to potential pedicular or vertebral breaches. Over 50,000 surgical procedures have been performed worldwide with DSG enabled devices. Numerous studies published in peer-reviewed medical and scientific journals have demonstrated the multiple benefits that PediGuard delivers to patients, surgical staff and hospitals. SpineGuard is expanding the scope of its DSG platform through strategic partnerships with innovative medical device companies and the development of smart instruments and implants. SpineGuard has offices in San Francisco and Paris. For further information, visit <u>www.spineguard.com</u>.

For further information, visit www.spineguard.com.

Disclaimer

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

Contacts

SpineGuard Pierre Jérôme Chief Executive Officer Tel: +33 (0)1 45 18 45 19 p.jerome@spineguard.com

Manuel Lanfossi Chief Financial Officer <u>m.lanfossi@spineguard.com</u>



Europe / NewCap Investor Relations & Financial Communication Florent Alba / Pierre Laurent Tel: +33 (0)1 44 71 94 94 <u>spineguard@newcap.fr</u>

<u>US</u>

Ronald Trahan, APR, Ronald Trahan Associates Inc. +1-508-359-4005, x108